Cellid, Co., Ltd. (KOSDAQ: 299660)

Market Cap	110.37B
Revenue (ttm)	2.28B
Net Income (ttm)	-10.06B
Shares Out	21.10M
EPS (ttm)	-688.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	274,503
Average Volume	841,920
Open	5,320.00
Previous Close	5,370.00
Day's Range	5,250.00 - 5,410.00
52-Week Range	1,733.00 - 17,310.00
Beta	1.43
RSI	43.65
Earnings Date	n/a

About Cellid,

Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 299660